Abstract:Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease phenotypes which start with simple steatosis and lipid accumulation in the hepatocytes - a typical histological lesions characteristic. It may progress to non-alcoholic steatohepatitis (NASH) that is characterized by hepatic inflammation and/or fibrosis and subsequent onset of NAFLD-related cirrhosis and hepatocellular carcinoma (HCC). Due to the central role of the liver in metabolism, NAFLD is regarded as a result of and contribution to the metabolic abnormalities seen in the metabolic syndrome. Peroxisome proliferator-activated receptors (PPARs) has three subtypes, which govern the expression of genes responsible for energy metabolism, cellular development, inflammation, and differentiation. The agonists of PPARα, such as fenofibrate and clofibrate, have been used as lipid-lowering drugs in clinical practice. Thiazolidinediones (TZDs) - ligands of PPARγ, such as rosiglitazone and pioglitazone, are also used in the treatment of type 2 diabetes (T2D) with insulin resistance (IR). Increasing evidence suggests that PPARβ/δ agonists have potential therapeutic effects in improving insulin sensitivity and lipid metabolism disorders. In addition, PPARs ligands have been considered as potential therapeutic drugs for hypertension, atherosclerosis (AS) or diabetic nephropathy. Their crucial biological roles dictate the significance of PPARs-targeting in medical research and drug discovery. Here, it reviews the biological activities, ligand selectivity and biological functions of the PPARs family, and discusses the relationship between PPARs and the pathogenesis of NAFLD and metabolic syndrome. This will open new possibilities for PPARs application in medicine, and provide a new idea for the treatment of fatty liver and related diseases.

FATP2-targeted therapies — A role beyond fatty liver disease

FATP2 Regulates Osteoclastogenesis by Increasing Lipid Metabolism and ROS Production.

FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase

Role of fatty acid transport protein 4 in metabolic tissues: insights into obesity and fatty liver disease

Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer

FATP2 activates PI3K/Akt/mTOR pathway by inhibiting ATF3 and promotes the occurrence and development of bladder cancer

Involvement Of Fatp2-Mediated Tubular Lipid Metabolic Reprogramming In Renal Fibrogenesis

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease.

Fatty Acid Transport Protein-5 (FATP5) Deficiency Enhances Hepatocellular Carcinoma Progression and Metastasis by Reprogramming Cellular Energy Metabolism and Regulating the AMPK-mTOR Signaling Pathway

Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors

Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets

Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)

Ubiquitin-like protein FAT10: A potential cardioprotective factor and novel therapeutic target in cancer.

The Biological Functions and Regulatory Mechanisms of Fatty Acid Binding Protein 5 in Various Diseases

Lipophagy and Liver Disease: New Perspectives to Better Understanding and Therapy.

Advances in the Research of Animal Fatty Acid Transport Protein 1

Fatty Acid Synthase Inhibitor Platensimycin Intervenes the Development of Nonalcoholic Fatty Liver Disease in a Mouse Model

The Emerging Roles of Fatty Acid Translocase/Cd36 and the Aryl Hydrocarbon Receptor in Fatty Liver Disease

The Regulation of TFEB in Lipid Homeostasis of Non-Alcoholic Fatty Liver Disease: Molecular Mechanism and Promising Therapeutic Targets

Role of Carnitine in Non-alcoholic Fatty Liver Disease and Other Related Diseases: An Update

PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients